piriprost and Shock

piriprost has been researched along with Shock* in 1 studies

Other Studies

1 other study(ies) available for piriprost and Shock

ArticleYear
Inhibitors of lipoxygenase products improve survival in traumatic shock.
    Prostaglandins, 1984, Volume: 28, Issue:4

    We have used three selective inhibitors of arachidonic acid metabolism in order to investigate the role of lipoxygenase metabolites in the pathogenesis of traumatic shock (LD90). The following inhibitors were used: CGS-5391B (2.5 mg/kg), a cyclooxygenase and lipoxygenase inhibitor, CGS-5677 (2.0 mg/kg), a selective lipoxygenase inhibitor, and U-60,257 (0.3 mg/kg), a putative inhibitor of glutathione-s-transferase. These inhibitors did not alter arterial blood pressure or heart rate when given to sham shock rats. The traumatic shock model was characterized by a 4.5-fold increase in plasma cathepsin D activity, a 4-fold increase in plasma myocardial depressant factor (MDF) activity, and a mean survival time of 1.5 +/- 0.2 h. Only the dual inhibitor significantly blunted the accumulation of cathepsin D in the plasma (7.5 +/- 0.8 vs 11.3 +/- 0.8 U/ml, p less than 0.01). However, all three inhibitors significantly suppressed plasma MDF accumulation by 50-60%: CGS-5391B, CGS-5677, and U-60,257 (p less than 0.01). Moreover, these three agents significantly improved survival time in traumatic shock. The increased survival time and reduced MDF activity afforded by these inhibitors suggest a significant role for lipoxygenase metabolites, particularly LTC4 and LTD4, in the pathogenesis of traumatic shock.

    Topics: Animals; Arachidonate Lipoxygenases; Benzothiepins; Blood Pressure; Cyclooxygenase Inhibitors; Epoprostenol; Heart; Lipoxygenase; Lipoxygenase Inhibitors; Male; Models, Biological; Organic Chemicals; Rats; Rats, Inbred Strains; Shock; Time Factors

1984